<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Mutations in the BRAF gene have been identified in approximately 7% of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, including 60% to 70% of <z:hpo ids='HP_0002861'>melanomas</z:hpo>, 29% to 83% of <z:hpo ids='HP_0002895'>papillary thyroid carcinomas</z:hpo>, 4% to 16% <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e>, and a lesser extent in serous ovarian and <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small cell lung cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The V600E mutation is found in the vast majority of cases and is an activating mutation, conferring transforming and immortalization potential to cells </plain></SENT>
<SENT sid="2" pm="."><plain>CEP-32496 is a potent BRAF inhibitor in an in vitro binding assay for mutated BRAF(V600E) (K(d) BRAF(V600E) = 14 nmol/L) and in a <z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated protein (MAP)/extracellular signal-regulated (ER) kinase (MEK) phosphorylation (pMEK) inhibition assay in human <z:hpo ids='HP_0002861'>melanoma</z:hpo> (A375) and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (Colo-205) cell lines (IC(50) = 78 and 60 nmol/L) </plain></SENT>
<SENT sid="3" pm="."><plain>In vitro, CEP-32496 has multikinase binding activity at other <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> targets of interest; however, it exhibits selective cellular cytotoxicity for BRAF(V600E) versus <z:mp ids='MP_0002169'>wild-type</z:mp> cells </plain></SENT>
<SENT sid="4" pm="."><plain>CEP-32496 is orally bioavailable in multiple preclinical species (&gt;95% in rats, dogs, and monkeys) and has single oral dose pharmacodynamic inhibition (10-55 mg/kg) of both pMEK and pERK in BRAF(V600E) colon <z:mp ids='MP_0002038'>carcinoma</z:mp> xenografts in <z:mp ids='MP_0003815'>nude</z:mp> mice </plain></SENT>
<SENT sid="5" pm="."><plain>Sustained <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> stasis and regressions are observed with oral administration (30-100 mg/kg twice daily) against BRAF(V600E) <z:hpo ids='HP_0002861'>melanoma</z:hpo> and colon <z:mp ids='MP_0002038'>carcinoma</z:mp> xenografts, with no adverse effects </plain></SENT>
<SENT sid="6" pm="."><plain>Little or no <z:mpath ids='MPATH_138'>epithelial hyperplasia</z:mpath> was observed in rodents and primates with prolonged oral administration and sustained exposure </plain></SENT>
<SENT sid="7" pm="."><plain>CEP-32496 benchmarks favorably with respect to other kinase inhibitors, including RAF-265 (phase I), <z:chebi fb="0" ids="50924">sorafenib</z:chebi>, (approved), and vemurafenib (PLX4032/RG7204, approved) </plain></SENT>
<SENT sid="8" pm="."><plain>CEP-32496 represents a novel and pharmacologically active BRAF inhibitor with a favorable side effect profile currently in clinical development </plain></SENT>
</text></document>